{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:05:55Z","timestamp":1769108755797,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00415-019-09492-w","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T11:19:50Z","timestamp":1564744790000},"page":"2807-2811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Idarucizumab administration in emergency situations: the Munich Registry of Reversal of Pradaxa\u00ae in clinical routine (MR REPAIR)"],"prefix":"10.1007","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3919-639X","authenticated-orcid":false,"given":"Clemens","family":"K\u00fcpper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Feil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Feuerecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"L\u00fccking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Thanbichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Zerkaulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitja","family":"Jandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Marziniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Poppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helge","family":"Topka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Kellert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"9492_CR1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, R-LS Committee Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"9492_CR2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1136\/jnnp-2018-318658","volume":"90","author":"D Giannandrea","year":"2019","unstructured":"Giannandrea D, Caponi C, Mengoni A, Romoli M, Marando C, Gallina A, Marsili E, Sacchini E, Mastrocola S, Padiglioni C, Mazzoli T, Cenciarelli S, Ricci S (2019) Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review. J Neurol Neurosurg Psychiatry 90:619\u2013623","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9492_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1177\/1747493017701944","volume":"12","author":"P Kermer","year":"2017","unstructured":"Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K, Berrouschot J, Cangur H, Daffertshofer M, Edelbusch S, Groschel K, Haase CG, Harloff A, Held V, Kauert A, Kraft P, Lenz A, Mullges W, Obermann M, Partowi S, Purrucker J, Ringleb PA, Rother J, Rossi R, Schafer N, Schneider A, Schuppner R, Seitz RJ, Szabo K, Wruck R (2017) Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany\u2014a national case collection. Int J Stroke 12:383\u2013391","journal-title":"Int J Stroke"},{"key":"9492_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack Jr","year":"2017","unstructured":"Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI (2017) Idarucizumab for dabigatran reversal\u2014full cohort analysis. N Engl J Med 377:431\u2013441","journal-title":"N Engl J Med"},{"key":"9492_CR5","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.05.004","volume":"27","author":"D Sanak","year":"2018","unstructured":"Sanak D, Jakubicek S, Cernik D, Herzig R, Kunas Z, Mikulik R, Ostry S, Reif M, Rohan V, Tomek A, Veverka T (2018) Intravenous thrombolysis in patients with acute ischemic stroke after a reversal of dabigatran anticoagulation with idarucizumab: a real-world clinical experience. J Stroke Cerebrovasc Dis 27:2479\u20132483","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"9492_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C, Investigators R-CIT (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764\u2013772","journal-title":"Circulation"},{"key":"9492_CR7","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.09.044","volume":"27","author":"LK Tsai","year":"2018","unstructured":"Tsai LK, Lin HJ, Chua SK, Liao PC, Yang YP, Chou PC, Lee CW, Lin MJ, Chen HM, Yeh JT, Li YH (2018) Real-world experience with idarucizumab to reverse anticoagulant effect in dabigatran-treated patients: report of 11 cases from Taiwan. J Stroke Cerebrovasc Dis 27:e27\u2013e33","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"9492_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/europace\/euy220","volume":"21","author":"SJ van der Wall","year":"2019","unstructured":"van der Wall SJ, van Rein N, van den Bemt B, Kruip M, Meijer K, Te Boome LCJ, Simmers TA, Alings AMW, Tieleman R, Klok FA, Huisman MV, Westerweel PE (2019) Performance of idarucizumab as antidote of dabigatran in daily clinical practice. Europace 21:414\u2013420","journal-title":"Europace"},{"key":"9492_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/14712598.2017.1349749","volume":"17","author":"O Vornicu","year":"2017","unstructured":"Vornicu O, Larock AS, Dincq AS, Douxfils J, Dogne JM, Mullier F, Lessire S (2017) Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. Expert Opin Biol Ther 17:1275\u20131296","journal-title":"Expert Opin Biol Ther"},{"key":"9492_CR10","doi-asserted-by":"crossref","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","volume":"5","author":"X Yao","year":"2016","unstructured":"Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA (2016) Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 5:e003725","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09492-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09492-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09492-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T01:59:16Z","timestamp":1664071156000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09492-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["9492"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09492-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"21 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"C.K, K.F., M.K., R.F., M.L., F.T., D.D., I.Z., M.J., M.M., H.P., S.W., H.T., and M.D. report no conflict of interest. L.K. has received funding for travel or speaker honoraria from Bayer Vital, Boehringer Ingelheim, Bristol-Meyer-Squibb, Daiichi Sankyo, and Pfizer outside of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the Institutional Review Board of the University of Munich (project no. 15\u2013075) and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Patients or their legal representatives gave written informed consent prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}